-
May 15, 2024
-
May 15, 2024
-
May 15, 2024
-
July 26, 2024
Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
-
July 24, 2024
-
July 23, 2024
-
July 16, 2024
EISAI ENTERS INTO LICENSE AGREEMENT FOR FOSRAVUCONAZOLE IN ASIA/OCEANIA WITH SATO PHARMA
-
July 12, 2024
“LEQEMBI®” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Israel
Latest Financial Reports
Consolidated Financial Report for Consolidated Annual Financial Report for Fiscal 2023
Financial Information
-
Management Policy
-
Value Creation Report (Former Integrated Report) / Environmental Report / Human Capital Report
-
Financial Data
Electronic Public Notice
No corporate bonds have been issued at present.